Evercyte ́s human urine-derived podocyte cell line PODO/SVTERT152 can be grown without limitations while maintaining expression of cell type specific markers and function. Therefore, these cells are valuable as standardized in vitro model to study kidney diseases such as glomerulopathies. Moreover, the cells are useful for toxicity studies in pre-clinical drug development as well as for the development of glomerulus-protective therapeutics.
General information
Cat#: CLHT-033-0152
Morphology
PODO/SVTERT152 cells are characterized by the typical, podocyte morphology.
Expression of marker proteins
FAQs
In vitro propagation
PodoUp3 medium (Evercyte, Cat# MHT-033-3)
MCDB131 (Pan Biotech, Cat# P04-80057)
1,6 mM GlutaMAX-I (Gibco, Cat# 35050-038)
9,6 µg/mL bovine brain extract (Lonza, Cat# CC-4098)
8 ng/ml hEGF (Sigma Aldrich, Cat# E9644)
20 ng/ml Hydrocortisone (Sigma Aldrich, Cat# H0396)
20% fetal bovine serum (PAN Biotech, Cat# P30-3031)
100 µg/ml G418 (InvivoGen, Cat# ant-gn-5)
Additional material & reagents
Phosphate buffered saline (PBS) (Sigma, Cat# D8537)
50 µg/ml collagen I (Sigma Aldrich, Cat# C2249), diluted in PBS
0,05 % Trypsin-EDTA (Gibco, Cat#25300-054)
Passaging of cells
The new culture flasks have to be pre-coated with human collagen I. Therefore, the culture flasks are pre-treated with collagen I solution (80 μl/cm²) at 37°C for at least 30 min.
Cryopreservation
Licence Conditions
The business concept of Evercyte is to out-license telomerized cells to our customers. The license conditions depend on whether the contract partner is a for profit or a nonprofit organization and the intended use of the cells.
Nonprofit organizations
On time payment for unlimited use: EUR 1600
Profit organizations
Pharmaceutical – chemical- cosmetic industries
Contract research organizations (CRO)
Initial license fee for 3 months: EUR 2500Annual license fee R&D: royalty based